ClinicalTrials.gg
WithdrawnNCT06028841Updated Dec 2, 2024

A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

A Phase 3 interventional study of VLA1553 in Chikungunya Virus Infection, sponsored by Valneva Austria GmbH. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 3, Interventional, and Prevention

Why this study was withdrawn
Withdrawn due to challenges related to recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Chikungunya Fever by Valneva — 2 open to participants now, 5 under way, 1 of them phase 3. Chikungunya Fever · Valneva.

Started
2024
the only one that year
Phase 3
5 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Chikungunya Fever by Valneva, this one is the only one that started in 2024, is one of 5 in phase 3, and was the 5th registered.

Chikungunya Fever

88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.

Browse Chikungunya Fever studies →

Open to participants now

2 of the 11 studies in Chikungunya Fever by Valneva are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Chikungunya Fever by Valneva, or all of them as a file.
02

Study summary

This was a phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of VLA1553 in moderately immunocompromised adults with HIV infection.

Read the detailed description

This was a multicenter, prospective, open-label, uncontrolled, single arm, phase 3 clinical study evaluating the final dose of VLA1553. The safety, tolerability, and immunogenicity of VLA1553 should have been assessed in moderately immunocompromised adult participants infected with HIV living in CHIKV endemic areas. Approximately 75 male and female adults (aged 18 years or above) infected with HIV should have been enrolled. Participants would have been screened by ELISA for evidence of previous CHIKV exposure excluding CHIKV seropositive participants from study participation.

03

Conditions studied

  • Chikungunya Virus Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who met ALL of the following criteria were eligible for this study:

  1. Adult participant aged 18 years or above infected with of either gender
  2. Participant has an understanding of the study and its procedures, agrees to its provisions, and voluntarily gives written prior to any study-related procedures
  3. Stage of disease A1, A2, B1 or B2 according to the revised CDC classification system for HIV infection from 1993 or Stages 1 or 2 in the absence of AIDS defining conditions (CDC update from 1994)
  4. Participants are recruited in Cohorts:

    1. For Cohort I:

      Participant has >350-≤400 cells/μL, is receiving antiretroviral therapy (ART) for at least 6 months and plasma HIV RNA \< 400 copies/ mL prior enrollment

    2. For Cohort II:

    Participant has CD4+ T cell counts >200 cells/μL (no upper limit), is receiving ART for at least 3 months and plasma HIV RNA \< 50 copies/ mL prior enrollment

  5. Participant is seronegative for previous CHIKV exposure (i.e. IgM- and IgG-) as screened by CHIKV-specific ELISA
  6. If female participant is of :

    1. Participant has a negative urine pregnancy test at screening (Visit 0) or Day 1 (Visit 1), respectively
    2. Participant has practiced an adequate method of during the 30 days before screening (Visit 0)
    3. Participant agrees to employ adequate birth control measures for the first three months post-vaccination (i.e. until Day 85, Visit 6).
  7. Female/male participant agrees to employ adequate birth control measures for the first three months post-vaccination (i.e., until Day 85, Visit 7)

Exclusion criteria

Exclusion Criteria:

Participants who met ANY of the following criteria were NOT eligible for this study:

  1. Participant is taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or has participated in a clinical study involving an CHIKV vaccine
  2. Participant has an acute or recent infection (and who is not symptom-free in the week prior to the Screening Visit (Visit 0) and Visit 1)
  3. Participant tests positive for (HIV) and fulfills AIDS indicator T cell counts or AIDS indicator conditions (disease stages C1, C2 or C3 or stage
  4. Participant tests positive for HIV with the actual target disease stages A1, A2, B1 or B2 (or stage 1 or 2), but was classified in the past at least once as fulfilling AIDS indicator conditions (disease stage C1, C2 or C3) or AIDS indicator T cell counts ( \<200/μL or CD4+ percentage \<14%)
  5. Participant tests PCR positive for active or virus (HCV)
  6. Participant has received any vaccine within 28 days prior to vaccination in this study or plans to receive any vaccine within 28 days after vaccination
  7. Participant has abnormal findings in any required study investigations (e.g. medical history, physical examination, and laboratory findings) considered by the Investigator and which pose a risk for participation in the study based on his/her judgement
  8. Participant currently has or had a history of significant cardiovascular, respiratory, metabolic, neurological, hepatic, rheumatic, , hematological, gastrointestinal or renal disorder (of note: Mild asthma that requires low dose inhalation only, during limited time periods of the year is not an exclusion criterion)
  9. Participant has an abnormal, clinically significant 12-lead at screening
  10. Participant has a history of immune-mediated or clinically relevant arthritis/arthralgia
  11. Participant has a history of
  12. Participant has a known or suspected defect of the immune system that can be expected to influence the immune response to the vaccine other than asymptomatic or moderately symptomatic HIV infection, such as participants with congenital immunodeficiency, status post organ transplantation or immuno-suppressive therapy within four weeks prior to Visit 1. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent ≥0.05 mg/kg/day within 4 weeks prior to study entry, radiation therapy or cytotoxic drugs/ monoclonal antibodies in the previous three years; topical and inhaled steroids are allowed
  13. Participant has a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known including febrile convulsions)
  14. Participant presents with clinical conditions representing a contraindication to intramuscular vaccination and blood draws
  15. Participant is pregnant (positive urine pregnancy test at screening or Visit 1, respectively), is lactating at the time of enrollment, has plans to become pregnant or subject's female partner plans to become pregnant during the first three months post-vaccination or practices unreliable
  16. Participant received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study
  17. Participant has a rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating
  18. Participant has participated in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to vaccination or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study
  19. Participant is a member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    VLA1553

    Biological: VLA1553

Interventions

  • BiologicalVLA1553

    Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose

06

What researchers measure

Primary outcomes

  1. Solicited adverse events

    Time frame: until Day 15

  2. To assess frequency and severity of unsolicited AEs

    Time frame: until Day 29 and Day 180 post-vaccination

  3. To assess frequency and relatedness of any serious adverse event (SAE)

    Time frame: until Day 180 post-vaccination

  4. To assess frequency and severity of any early onset adverse event of special interest (AESI)

    Time frame: within 2 to 21 days post-vaccination (i.e. Day 3 - Day 22)

  5. To assess frequency and severity of any late onset adverse event of special interest (AESI) during the entire study

    Time frame: starting 22 days post-vaccination (i.e. Day 23 - Day 180)

  6. To assess CHIKV viremia

    Time frame: on Days 1, 4, 8 and 15 (Day 29 and Day 57, if applicable)

  7. To assess HIV viral load

    Time frame: on Days 1, 15, 29, 57, 85, and 180

Secondary outcomes

  1. Immune response as measured by CHIKV-specific neutralizing antibody titers post-vaccination as determined by μPRNT assay

    Time frame: Day 15, Day 29, Day 57, Day 85 and Day 180

  2. Proportion of participants with seroresponse levels post-vaccination as determined by μPRNT assay

    Time frame: Day 15, Day 29, Day 57, Day 85 and Day 180

  3. Proportion of participants with seroconversion as compared to baseline as determined by μPRNT assay

    Time frame: Day 29 and Day 180

  4. Fold increase of CHIKV-specific neutralizing antibody titers determined by μPRNT assay post-vaccination as compared to baseline

    Time frame: Day 15, Day 29, Day 57, Day 85 and Day 180

  5. Proportion of participants reaching an at least 4-fold, 8-fold, 16-fold or 64-fold increase in CHIKV-specific neutralizing antibody titer compared to baseline as measured by μPRNT assay

    Time frame: Day 15, Day 29, Day 57, Day 85 and Day 180

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Aug 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Sep 8, 2023
StartActual
Apr 10, 2024
Primary completionActual
Aug 27, 2024
CompletionActual
Aug 27, 2024
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06028841
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Apr 10, 2024
Primary completion
Aug 27, 2024
Completion
Aug 27, 2024
Last update
Dec 2, 2024

Study contacts

Valneva Clinical Development
study chair · Valneva Austria GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chikungunya vaccine

Start the discussion